TECH BIO-TECHNE Corp
Price (delayed)
$64.92
Market cap
$10.26B
P/E Ratio
64.92
Dividend/share
$0.32
EPS
$1
Enterprise value
$10.48B
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's
Highlights
BIO-TECHNE's debt has decreased by 29% YoY
TECH's P/E is 7% below its last 4 quarters average of 69.6
TECH's EPS is down by 29% year-on-year but it is up by 5% since the previous quarter
The net income has decreased by 29% YoY but it has increased by 4.9% from the previous quarter
The quick ratio has declined by 15% since the previous quarter and by 3.5% year-on-year
The gross margin has declined by 2.2% year-on-year
Key stats
What are the main financial stats of TECH
Market
Valuations
Earnings
Shares outstanding
158.09M
Market cap
$10.26B
Enterprise value
$10.48B
Price to earnings (P/E)
64.92
Price to book (P/B)
4.96
Price to sales (P/S)
8.6
EV/EBIT
52.01
EV/EBITDA
33.58
EV/Sales
8.76
Revenue
$1.2B
Gross profit
$784.85M
Operating income
$200.23M
Net income
$158.14M
EBIT
$201.53M
EBITDA
$312.12M
Free cash flow
$254.3M
Per share
Balance sheet
Liquidity
EPS
$1
EPS diluted
$1
Free cash flow per share
$1.61
Book value per share
$13.08
Revenue per share
$7.55
TBVPS
$7.86
Total assets
$2.67B
Total liabilities
$591.93M
Debt
$395.13M
Equity
$2.08B
Working capital
$473.38M
Debt to equity
0.19
Current ratio
3.94
Quick ratio
2.45
Net debt/EBITDA
0.7
Margins
Efficiency
Dividend
EBITDA margin
26.1%
Gross margin
65.6%
Net margin
13.2%
Operating margin
16.7%
Return on assets
5.8%
Return on equity
7.6%
Return on invested capital
14.9%
Return on capital employed
8%
Return on sales
16.8%
Dividend yield
0.49%
DPS
$0.32
Payout ratio
32%
TECH stock price
How has the BIO-TECHNE stock price performed over time
Intraday
-0.87%
1 week
-1.55%
1 month
-17.56%
1 year
-9.48%
YTD
-9.87%
QTD
-9.87%
Financial performance
How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.2B
Gross profit
$784.85M
Operating income
$200.23M
Net income
$158.14M
Gross margin
65.6%
Net margin
13.2%
BIO-TECHNE's net margin has decreased by 33% YoY but it has increased by 2.3% QoQ
BIO-TECHNE's operating margin has decreased by 29% YoY but it has increased by 2.5% QoQ
The net income has decreased by 29% YoY but it has increased by 4.9% from the previous quarter
The company's operating income fell by 25% YoY but it rose by 4.9% QoQ
Growth
What is BIO-TECHNE's growth rate over time
Valuation
What is BIO-TECHNE stock price valuation
P/E
64.92
P/B
4.96
P/S
8.6
EV/EBIT
52.01
EV/EBITDA
33.58
EV/Sales
8.76
TECH's EPS is down by 29% year-on-year but it is up by 5% since the previous quarter
TECH's P/E is 7% below its last 4 quarters average of 69.6
The stock's price to book (P/B) is 34% less than its 5-year quarterly average of 7.5 and 11% less than its last 4 quarters average of 5.6
BIO-TECHNE's equity has increased by 6% YoY but it has decreased by 2.8% from the previous quarter
The price to sales (P/S) is 33% lower than the 5-year quarterly average of 12.9 and 13% lower than the last 4 quarters average of 9.9
The revenue has grown by 4.5% YoY and by 2.1% from the previous quarter
Efficiency
How efficient is BIO-TECHNE business performance
BIO-TECHNE's return on equity has decreased by 34% YoY but it has increased by 2.7% QoQ
TECH's return on assets is down by 31% year-on-year but it is up by 5% since the previous quarter
TECH's return on sales is down by 27% year-on-year but it is up by 2.4% since the previous quarter
BIO-TECHNE's ROIC has decreased by 19% YoY but it has increased by 9% from the previous quarter
Dividends
What is TECH's dividend history
DPS
$0.32
Dividend yield
0.49%
Payout ratio
32%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did BIO-TECHNE financials performed over time
BIO-TECHNE's total liabilities has decreased by 23% YoY
The quick ratio has declined by 15% since the previous quarter and by 3.5% year-on-year
BIO-TECHNE's debt is 81% lower than its equity
TECH's debt to equity is down by 32% year-on-year
BIO-TECHNE's debt has decreased by 29% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.